Venatorx suffered a setback in February when its new drug application for a urinary tract infection treatment was rejected by ...
providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole ...
Operator: Hello and welcome to the Iterum Therapeutics First Quarter 2024 Financial Results and Business Update. My name is Carla, and I ...
Research and development (R&D) expenses for the first quarter 2024 were $4.0 million compared to $6.4 million for the same period in 2023. The decrease for the three-month period was primarily due to ...
Q1 2024 Earnings Call Transcript May 14, 2024 Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals, Inc. First Quarter of 2024 Results Conference Call [Operator Instructions]. As ...
In February 2024, the U.S. Food and Drug Administration (FDA) cleared the Company’s Investigational New Drug (IND) application to advance SPR206 into a Phase 2 clinical trial in participants with ...
The Optilume ® BPH Catheter System is a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery ...
It's the latest move to make access to medication abortions more widely available as the Supreme Court weighs whether to ...
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall ...
Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients ...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, ...
Upleganan is a small molecule commercialized by Everest Medicines, with a leading Phase I program in Acinetobacter Infections.